CIENCIASMEDICASNEWS

Quantum techniques offer a glimpse of next-generation medicine Quantum-informed AI could open up unexplored chemical space, speeding the design of safer, more effective drugs.

https://www.drugdiscoverynews.com/quantum-techniques-offer-a-glimpse-of-next-generation-medicine-16815?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_4ohn1Rh86Av1dDd0FclJngmb4vJcSCDvwFCGHTDv0t2qqa-Y_7B2H0XhFnA5e4EIZfpZ9XwBpgMuvndjA3peWoJcEIw&_hsmi=411298769&utm_content=411298769&utm_source=hs_email Today, QSimulate, a biotech software company that develops quantum-informed simulation tools, announced a new round of financing that brings its total funding to over $11 million and simultaneously unveiled QUELO v2.3, the latest version of its quantum-enabled molecular simulation platform. The news signals that quantum mechanics is rapidly moving from a theoretical aspiration to a practical engine for pharmaceutical innovation. How multi-omics is redefining proteomics and precision discovery Transcriptomics, proteomics, and functional genomics are converging to create a new era of mechanism-aware drug discovery. https://www.drugdiscoverynews.com/how-multi-omics-is-redefining-proteomics-and-precision-discovery-16791?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_CI5s9FiP73vK25wn3IYJ_J-amkWWuiEZQDxecuNV7ldcj_YyNbuNA6ccYhDhkcRDZQWEDBTt8SHJzMDV17FLPf0SM2Q&_hsmi=411298769&utm_content=411298769&utm_source=hs_email After two decades dominated by genomics, the field’s attention has shifted toward understanding how genetic blueprints translate into functional, dynamic proteins — and how those proteins interact, fold, misfire, or evolve in the complex environment of living cells. Proteomics is now taking center stage and becoming the connective tissue that links the cell’s instructions to its outcomes.

The growing role of multi-omics within drug discovery Harnessing multi-omics and AI, researchers are transforming drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development.

https://www.drugdiscoverynews.com/the-growing-role-of-multi-omics-within-drug-discovery-17097 Drug discovery has long been a high-risk, high-reward endeavor. Developing a new therapeutic from initial concept to market approval can take over a decade and cost more than $2 billion on average. Despite these staggering investments, the failure rate remains high, with many drugs faltering in late-stage clinical trials due to unforeseen toxicity, lack of efficacy, or poor patient stratification. Traditional approaches often focus on targeting a single molecule or pathway, an approach increasingly recognized as insufficient for tackling complex diseases such as cancer, neurodegeneration, and autoimmune disorders.

The future of gene therapy depends on mastering in vivo delivery At the Advanced Therapies conference, industry leaders showcased how in vivo CAR T cell and gene delivery innovations could transform accessibility and clinical outcomes.

https://www.drugdiscoverynews.com/the-future-of-gene-therapy-depends-on-mastering-in-vivo-delivery-17102 Over the past decade, chimeric antigen receptor (CAR) T cell therapy has emerged as one of the most transformative innovations in cancer treatment, harnessing the immune system’s power to target and eliminate malignant cells. By redirecting patient-derived T cells to recognize specific antigens, CAR T therapies have achieved remarkable success in hematologic malignancies, particularly in refractory disease.

Making it easier for patients living with rare diseases to find the right specialist

https://rarerevolutionmagazine.com/making-it-easier-for-patients-living-with-rare-diseases-to-find-the-right-specialist/ For people living with rare diseases, the longest and most difficult delays often happen before treatment ever begins. Rare disease journeys are rarely linear. Patients and caregivers may spend years navigating uncertainty, misdiagnosis and fragmented care before they ever reach the right clinician. Research suggests that, on average, it can take five or more years1 to receive an accurate rare disease diagnosis, during which time they may see six physicians2 or more. Along the way, misdiagnosis and fragmented care are well documented, often contributing to worse outcomes and eroding trust in the healthcare system.